« Previous
Next »
Titles
- 340B Drug Discount Program: oversight of the Intersection with the Medicaid Drug Rebate Program needs improvement : report to Congressional requesters1
- 510(k) third party review program: guidance for industry, Food and Drug Administration staff, and third party review organizations1
- A pathway to full integration of care for Medicare-Medicaid beneficiaries1
- ANDA submissions: amendments and requests for final approval to tentatively approved ANDAs1
- Access and use of electronic health information by individuals with cancer: 2017-20181
- Access to Medicare Part D plans: a comparison of metropolitan and nonmetropolitan areas1
- Advance care planning among Medicare fee-for-service beneficiaries and practitioners: final report1
- Advancing comprehensive primary care in Medicaid1
- Air travel and communicable diseases: status of research efforts and action still needed to develop federal preparedness plan : testimony before the Subcommittee on Space and Aeronautics, Committee on Science, Space, and Technology, House of Representatives1
- Alternative procedures for blood and blood components during the COVID-19 public health emergency1
- Anesthesia services: differences between private and Medicare payments likely due to providers' strong negotiating position : report to Congressional committees1
- Antibiotic resistance: additional federal actions needed to better determine magnitude and reduce impact1
- Arkansas Medicaid Fraud Control Unit: 2019 onsite inspection1
- Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment1
- Assessing user fees under the Biosimilar User Fee Amendments of 20171
- Assessing user fees under the prescription drug user fee amendments of 20171
- Basic safety and essential performance of medical electrical equipment, medical electrical systems, and laboratory medical equipment: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1
- Best practices in developing proprietary names for human prescription drug products1
- Billions in estimated Medicare Advantage payments from diagnoses reported only on health risk assessments raise concerns1
- Biocompatibility testing of medical devices: standards specific information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program : guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1